FDA Submission Update for SCOMARA (Sirolimus) by AFT Pharmaceuticals
AFT Pharmaceuticals has submitted New Drug Application (NDA) for SCOMARA, an sirolimus-based therapy.
Company
Pharmaceutical intelligence for AFT Pharmaceuticals with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.